Cardinal Health, IncNYSE: CAH
Health Care · Health Care Distributors
$195.26
+1.23%
Vol: 1.6M
Research Digest
Friday, May 1, 2026
Cardinal Health reported Q3 FY2026 adjusted EPS of $3.17, beating consensus of $2.79, but missed revenue of $60.9B vs. $61.7B expected.
Cardinal Health reported mixed Q3 FY2026 results on April 30 with adjusted EPS of $3.17, beating consensus of $2.79, but revenue of $60.9 billion missed expectations of $61.7 billion. However, the company raised and narrowed FY2026 non-GAAP EPS guidance to $10.70-$10.80. Specialty segment revenue grew over 20%. Challenges included a 35% YoY decline in Global Medical Products profit largely due to tariffs. Despite beating EPS, stock fell 4.83% post-earnings on revenue miss.
Previous Market Intelligence
13 daysApr 30Cardinal Health Q3 2026 beats EPS estimates, raises full-year guidance amid specialty pharma demandPositive▶
Cardinal Health posted Q3 2026 earnings of $3.17 per share, beating estimates of $2.82 by $0.35, demonstrating strong operational performance. Q3 revenues reached $65.6 billion, up 19% year-over-year, with double-digit growth in pharma and specialty services. Non-GAAP operating earnings increased 38% to $877 million and non-GAAP diluted EPS rose 36% to $2.63. The company raised full-year fiscal 2026 EPS guidance to $10.15-$10.35, representing 23-26% growth. Cardinal Health expanded Actinium-225 production capacity at its Indianapolis facility, quadrupling weekly output since end of 2024. Patricia A. Hemingway Hall was appointed Board Chair. Analyst consensus 12-month price target is $232.27.
Apr 29Cardinal Health beats Q1 revenue expectations with 18.8% YoY growth; reports earnings tomorrowPositive▶
Cardinal Health reported Q2 results with revenue of $65.63 billion (+18.8% YoY) and adjusted EPS up 36%. The company beat analyst revenue expectations and raised full-year earnings guidance. Patricia A. Hemingway Hall appointed as Board Chair. Cardinal Health expanded Actinium-225 production capacity for novel cancer therapies and reported growing momentum in advanced therapies for community care settings. Q1 earnings report scheduled for Thursday, April 30 before market open. Analysts are increasingly bullish with majority upward revenue revisions in past 30 days.
Apr 16Cardinal Health Q3 FY2026 results due April 30; company expanded Actinium-225 production capacity and released advanced therapies expansion report.Positive▶
Cardinal Health released its 2026 Advanced Therapies Report on April 14 highlighting momentum in expanding life-changing treatments into community settings; 61 advanced therapies are currently approved in the US with that number expected to nearly triple by 2030. On April 1, the company announced expansion of its Actinium-225 (Ac-225) production capabilities at its Center for Theranostics Advancement in Indianapolis, adding a high-capacity production line to support Ac-225 drug products in development for multiple cancer types. Board approved quarterly dividend of $0.5107/share payable April 15. Q3 FY2026 earnings due April 30. Stock recently up 1.44% with average analyst rating of 'Buy' and 12-month price target of $232.27 (+9.65% upside).
Apr 15Cardinal Health released 2026 Advanced Therapies Report projecting 61 approved therapies could nearly triple to 180 by 2030, with Q3 earnings due April 30.Positive▶
Cardinal Health released its 2026 Advanced Therapies Report on April 14, noting 61 advanced therapies are currently approved in the U.S., expected to nearly triple to approximately 180 by 2030. Cardinal Health also expanded Actinium-225 production capacity at its Indianapolis center. Board approved a quarterly dividend of $0.5107 per share payable April 15, 2026. Q3 fiscal 2026 results will be announced April 30, 2026.
Apr 14Cardinal Health expands Actinium-225 production capacity for targeted alpha therapies and plans Q3 fiscal 2026 earnings release on April 30.Positive▶
Cardinal Health announced a major expansion of Actinium-225 production at its Center for Theranostics Advancement in Indianapolis. This expansion supports over 15 clinical trials worldwide and strengthens Cardinal Health role as a radiopharmaceutical partner for oncology developers. The Board approved a quarterly dividend of $0.5107 per share. Q3 FY2026 results are scheduled for April 30. The company reported strong Q2 2026 earnings of $2.63 per share vs. $2.34 estimate (12.35% beat) and revenue of $65.6B (+18.75% YoY).
Apr 13Cardinal Health raises FY2026 profit guidance after Q1 beat; Actinium-225 production expands for targeted cancer therapies.Positive▶
Cardinal Health exceeded first-quarter 2026 earnings expectations with adjusted EPS of $2.55, beating consensus estimates. The company raised its annual adjusted profit forecast on strong demand for specialty and branded drugs. In early April, Cardinal Health announced a major expansion of Actinium-225 capacity at its Indianapolis facility. Q3 earnings scheduled for April 30. Analyst consensus rating of Buy with $230.45 price target.
Apr 10Cardinal Health expands Actinium-225 production capacity for targeted alpha therapies; Q3 earnings due April 30.Positive▶
Cardinal Health announced major expansion of Actinium-225 (Ac-225) production at its Center for Theranostics Advancement in Indianapolis. The company has quadrupled weekly output since end of 2024. Strong pharma demand is driving 19% revenue growth and 29% profit growth in the Pharmaceutical segment. Evercore ISI maintained Outperform rating but lowered price target from $260 to $240.
Apr 9Cardinal Health faces federal discrimination lawsuit from supervisor over alleged age and gender biasMixed▶
Cardinal Health is facing a federal lawsuit filed April 1 in U.S. District Court for the Southern District of Ohio from a long-tenured supervisor alleging wrongful termination based on age and gender discrimination. This legal challenge follows strong financial performance with Q2 results showing 18.8% sales growth and 36% EPS rise, plus raised full-year earnings guidance. Evercore ISI lowered price target to $240 from higher estimates, though average analyst consensus remains "Outperform" with 12-month target of $249.83. Company reported 2.63 EPS last quarter versus 2.34 estimate, demonstrating solid operational strength despite employment litigation risk.
Apr 8Cardinal Health expands Actinium-225 production 4x capacity, Q3 FY2026 earnings set for April 30Positive▶
Cardinal Health announced major expansion of Actinium-225 (Ac-225) production capacity at its Center for Theranostics Advancement in Indianapolis, adding a high-capacity production line to its Drug Master File. Since end-2024, Cardinal Health quadrupled weekly Ac-225 output to meet growing demand for targeted alpha therapies in cancer treatment. The company declared a $0.5107 quarterly dividend payable April 15. Q3 fiscal 2026 results will be released April 30 before NYSE open with investor call at 8:30 a.m. ET. Analyst consensus is 'Buy' with $230.45 PT (+5.8% upside). Ac-225 capacity expansion supports high-margin specialty pharmaceutical growth but execution on production timelines and commercial adoption are critical metrics.
Apr 7Cardinal Health expands Actinium-225 cancer therapy production capacity in Indianapolis.Positive▶
Cardinal Health expanded Ac-225 production at Indianapolis Center for Theranostics Advancement. Supports 15+ clinical trials. EPS estimates for 2026 raised 11.2% to $4.46 in past 30 days. Stock $206.58, down 0.54%.
Apr 6Cardinal Health acquires Solaris Health; releases 2026 biosimilars report amid dividend and leadership changes.Positive▶
Cardinal Health (CAH) stock trades at $206.58, down 0.54% in 24 hours, with 11 analysts rating "Buy" and average 12-month target of $230.45 (+5.82%). The company completed acquisition of Solaris Health (Nov 2025), integrating 750+ providers across 250+ practices in 14 states into its MSO platform. Cardinal Health released its 2026 Biosimilars Report showing $56B in U.S. savings since 2015 and projecting $181B future savings if market conditions align. A Chief Accounting Officer transition was announced (March 5, 2026). The quarterly dividend stands at $0.5107/share from capital surplus. Healthcare sector strength continues to support CAH despite insider selling activity, with near-term upside potential.
Apr 3Biosimilars leadership and Actinium-225 expansion drive Cardinal Health forward; Q3 earnings due April 30.Neutral▶
Cardinal Health appointed Patricia A. Hemingway Hall as new Board Chair. The company is expanding Actinium-225 radioisotope production capacity for targeted alpha therapies. Cardinal Health released its 2026 Biosimilars Report highlighting $56B in cumulative US savings. Q3 FY2026 earnings will be released April 30. The board approved a quarterly dividend of $0.5107 per share.
Apr 2Cardinal Health Q2 FY2026 revenue $65.6B (+19% YoY); Board approved $0.5107 quarterly dividend payable April 15.Positive▶
Cardinal Health reported Q2 FY2026 revenue of $65.6 billion, up 19% year-over-year, with GAAP operating earnings of $707 million (+29%) and diluted EPS of $1.97 (+19%). Board approved quarterly dividend of $0.5107 per share payable April 15 to shareholders of record April 1. Company released 2026 Biosimilars Report highlighting $56 billion in U.S. savings since 2015 and projecting up to $181 billion in future savings. Stock at $206.58, down 0.54% in last 24 hours. Q3 FY2026 results due April 30, 2026.
Sector Peers
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| MCKMCKESSON | $815.42 | +0.03% | -4.8% | 18.5x | 0.42 | $99.9B |
| CORCENCORA | $305.04 | -0.96% | -4.0% | 15.7x | 0.72 | $59.9B |
| CAHCARDINAL | $195.26 | +1.23% | -9.3% | 16.6x | 0.65 | $45.4B |
| HSICHENRY | $74.09 | -0.68% | -0.4% | 12.7x | 0.88 | $8.6B |
| LLYELI | $964.50 | +3.20% | +0.8% | 22.2x | 0.50 | $834.9B |
| JNJJOHNSON | $227.78 | -0.90% | -4.6% | 18.1x | 0.33 | $553.3B |
Key Fundamentals
RSI (14-Day)
52-Week Range
Moving Averages
Price between 50d and 200d. Testing 50d support.